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The skeleton is the most frequent target for metastases in 
breast cancer (Meissner et al, 1971; Bonadonna et al, 1993). Many
breast cancer patients are also affected by chronic degenerative,
inflammatory or metabolic lesions of bone, joint or muscle
(osteoarthritis, osteoporosis, myositis, fibrositis, rheumatoid
arthritis, sarcoidosis, etc) due to the relatively advanced age of this
population. Chronic or transient non-neoplastic bone symptoma-
tology can mimic the metastatic bone involvement in breast cancer
and vice versa. So far no humoral indicator derived from bone has
proved reliable for the differential diagnosis of neoplastic bone
involvement (Cuschieri, 1973; Gielen et al, 1976; Cuschieri, 1977;
White et al, 1979; Mundy et al, 1984; Touitou et al, 1985). Skeletal
X-rays are not a suitable tool for the ‘early’ diagnosis of bone
metastases because they only detect lesions when the loss of
calcium is at least 30–50% (Guzzo et al, 1969; Cuschieri, 1973;
Gielen et al, 1976). Bone scintigraphy (BS) with 99mTc bisphos-
phonates has a high sensitivity, however it also has a low speci-
ficity (Fogelman, 1991; Robinson, 1998) and it often demonstrates
hot spots in those patients who remain permanently disease-free.
The more recently developed diagnostic imaging techniques such
as computed tomography (CT) and nuclear magnetic resonance
(NMR), although helpful in the study of bony lesions (Colman et
al, 1988; Nicolini et al, 1992), may not be used in all the patients
with suspected metastatic disease because they are expensive and
time-consuming.
Thus, in breast cancer patients efforts for the diagnosis and
monitoring of bone metastases lead to a great number of ineffec-
tive, expensive and potentially harmful radiological examinations.
Therefore, efforts to improve the accuracy in distinguishing
benign from metastatic bone involvement are of great potential
utility. In addition, the ‘early’ detection and treatment of distant
metastases is useful in prolonging disease-free interval and overall
survival of some breast cancer patients (Nicolini et al, 1997).
In recent decades the serum concentration of tumour markers
has been used as a warning sign of distant metastases (Nicolini 
et al, 1989; 1992; 1997); the combination of carcinoembryonic
antigen (CEA), tissue polypeptide antigen (TPA) and breast
cancer-associated antigen 115 D8/DF3 (CA 15.3) has shown 87%
sensitivity in the ‘early’ detection of breast cancer relapses with
78% positive predictive value (Nicolini et al, 1991). Since 1986
we have adopted a protocol based upon the results of the CEA-
TPA-CA15.3 tumour marker panel in the characterization of
patients with equivocal BS. The aim of this study is to assess the
value of a protocol based on serial determination of the serum
CEA-TPA-CA15.3 tumour marker panel to identify, among the
breast cancer patients with equivocal BS, those affected by bone
metastases or at high risk of developing bone metastases.
MATERIALS AND METHODS
Patients
Between January 1986 and December 1995, 297 breast cancer
patients aged 29–80 years were studied postoperatively. At post-
operative histology, 116 patients showed axillary lymph-node
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Correspondence to: A Nicoliniinvolvement (N+) and 169 did not (N–). In the remaining 12
patients, skeletal metastases were found at the time of surgery
(M1). The mean follow-up time was 84 months (range 8–120).
Following mastectomy the patients were studied every 6 or
4 months according to whether they were N– or N+ at pathological
examination. ER and PR were determined on tumour tissue. ER-
and PR- patients were allocated to the shorter interval for follow-
up. Initially the serum CEA-TPA-CA15.3 determination, routine
blood tests (ESR, glucose, calcium, phosphorus, blood cell count,
BUN, creatinine, GOT, GPT, gamma GT, bilirubin, alkaline phos-
phatase, immunoglobulins), chest X-ray, BS, liver echography and
a detailed history and clinical examination were carried out to
better define the postoperative staging. Baseline skeletal
X-ray was performed to distinguish the benign lesions due to
inflammatory and/or degenerative disease in the follow-up.
Subsequently, at each visit, the CEA-TPA-CA15.3 tumour marker
panel, the clinical and routine laboratory examinations were
performed in addition to the history; BS and liver echography
were carried out at the 24-month interval. When a relapse was
suspected by tumour marker panel, BS and liver echography were
performed immediately.
All invasive procedures were avoided except fine needle aspira-
tion which was carried out at the sternum in two patients. In
patients with typical metastatic or negative BS, bone metastases
were considered to be diagnosed or ruled out respectively.
Tumour markers
The TPA was measured by the Sangtec Medical (Bromma,
Sweden) commercial kit. Serum levels initially > 60 mU ml–1 and
subsequently > 85 mU ml–1 were considered elevated. Serum
CA15.3 concentrations were determined by IRMA (Cis
International) using a commercial kit and 32 U ml–1 was taken as
the cut-off level. CEA was measured by Lepetit Lysophase RIA
(Milano, Italy) and subsequently by Sorin Biomedica (Saluggia,
Italy) commercial kits; both methods gave superimposable results
in appropriate comparative studies. Serum levels > 7 ng ml–1 were
considered elevated. The within and between assay coefficients of
variation for CEA, TPA and CA15.3 were less than 6% and 9%
respectively. When the TPA cut-off value was 60 mU ml–1 the
coefficients of variation increased to 10% and 15% respectively. In
our clinical study the serum tumour marker level itself was much
less important than their time-related change.
A dynamic evaluation of tumour markers was made and in cases
of a high tumour marker value a further blood sample was drawn
within a month of the previous elevated value. If the initial
elevated tumour marker value decreased to a normal level this was
considered to be an isolated elevated value. The increase in tumour
marker was considered to be progressive when it was > 30% in the
sample following the initial elevated value. Otherwise, two high
values were regarded to be a constant elevation. Only patients with
constant elevation or progressive increase in one or more tumour
markers, unexplained by concomitant benign pathology and by
history, were considered to be suspicious of tumour relapse
(Nicolini et al, 1989; 1991; 1997).
Bone scintigraphy
BS was performed 2–3 h after injection of 15–20 mCi 99mTc
hydroxymethyldiphosphonate (HMDP) and bone imaging was
performed initially with an analogue and then a digital whole-body
gamma camera (models SELO KR7 and General Electrics
STARCAM 400 or 3000 respectively). In order to better interpret
the BS findings, the history and benign lesions (osteoarthritis,
osteoporosis, trauma, etc) detected with baseline skeletal X-ray
were taken into account. The principal criteria for interpretation of
the BS and the principal types of BS patterns were as follows.
• Findings very likely due to bone metastases (pathological
BS): multiple obvious hot spots in sites that are usual for
breast cancer metastases and not involved by benign lesions.
• Findings very likely not due to bone metastases (negative
BS): no hot spot; one or more hot spots with diffuse irregular
uptake; one or more hot spots in sites that are unusual for
breast cancer metastases and involved by benign lesions.
• Findings defined as equivocal for bone metastases (equivocal
BS): slight asymmetry of tracer uptake; one or more hot spots
in sites that are unusual for breast cancer metastases (skull,
arms) and not involved by benign lesions; one or more hot
spots in sites that are usual for breast cancer metastases also
involved by benign lesions; a single hot spot in sites that are
usual for breast cancer metastases and not involved by benign
lesions.
Management of patients with equivocal BS
Patients with equivocal BS and concomitant constant elevation or
progressive increase in one or more tumour markers were selected
for radiological examinations. Constant elevation or progressive
increase in tumour markers were defined as mentioned above. All
hot spots on the BS with an equivocal interpretation and selected
for radiological examination were examined by CT, except those
in the ribs that were evaluated by skeletal X-ray. Skeletal X-ray
and CT were carried out according to standard techniques.
Specifically, for CT performed using a CT SYTEC 3000 GE, slice
thickness was 1 mm, spacing 1 mm and scan time 2 s, and for a
CT 9800 QUICK, high resolution, slice thickness 1.5 mm, spacing
3 mm and scan time 2 s.
Statistical analysis
Probably positive tests were defined as: (a) radiological examina-
tion (i.e. baseline skeletal X-ray, skeletal X-ray and CT directed to
the hot spots of BS) that was pathological or baseline skeletal
X-ray that showed a picture of equivocal interpretation and (b)
tumour marker assay panel with constant elevation or progressive
increase in one or more antigens, unexplained by concomitant
transient or chronic benign pathology. Pathological BS and those
showing a picture of equivocal interpretation were also considered
probably positive tests. Probably positive tests which were
confirmed by monitoring to death or by a definite clinical-imaging
course after the initial result were defined as true positives.
Probably negative tests were defined as: (a) negative radio-
logical examination and negative BS and (b) CT without definitely
abnormal result and (c) tumour marker assay panel with normal or
isolated elevated value that persisted longer than 6 months after
the first abnormal result. Probably negative tests which were
followed by at least 1 year of survival without any clinical-
imaging signs of relapse were evaluated as true negatives.
In patients where CT and/or skeletal X-ray were directed to
multiple BS areas with equivocal interpretation, a single test result
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it was negative in all uncertain BS areas, equivocal or pathological
when it was uncertain or pathological in at least one of the BS
areas with equivocal interpretation. The final result was related to
the most relevant of the equivocal BS areas evaluated by CT
and/or skeletal X-ray.
Sensitivity was defined as TP/(TP + FN) ´ 100, specificity as
TN/(TN + FP) ´ 100, accuracy as TN + TP/(TN + FN + TP + FP),
positive predictive value as TP/(TP + FP), negative predictive
value as TN/(TN + FN), where FP = false positive, FN = false
negative, TP = true positive, TN = true negative.
In patients with a BS with equivocal interpretation the exact
Fisher’s test was applied to verify whether tumour marker panel
had statistically significant power in distinguishing true positives
from true negatives.
RESULTS
General outcome and BS with equivocal interpretation
Up to December 1995, 47 (16%) of the 297 patients manifested
distant metastases and in 35 of them these occurred during the
postoperative follow-up. Twenty five of these 35 patients were N+
and the remaining 10 N–. In 42 of the 47 patients with metastases,
bone was the first site of distant spread. In the other five, various
organs were involved contemporaneously with bone.
During the postoperative follow-up 158 (53%) of the 297
patients showed hot spots on BS with equivocal interpretation.
One hundred and thirty-six of them (86%) (group a) were in the
250 non-relapsed patients and the remaining 22 (14%) (group b)
were in the group of 47 with bone metastases. Twenty-four (15%)
of these 158 patients, six (4%) in group a (non-relapsed) and 18
(82%) in group b (bone metastases), were selected on the basis of
constant elevation or progressive increase in one or more of
tumour marker panel to undergo CT or skeletal X-ray directed
towards BS hot spots with equivocal interpretation.
Non-relapsed patients
Table 1 shows the principal results of tests performed in the 250
non-relapsed patients. In these patients the overall specificities for
excluding bone metastases of baseline skeletal X-ray, BS and
tumour marker panel were 97%, 46% and 99% respectively.
One hundred and thirty-six (54%) (group a) of these non-
relapsed patients had hot spots on BS with equivocal interpreta-
tion. In that group a, aged 33–80 years (57 ± 12; mean ± SD), 32%
of patients were premenopausal and 68% were N+, and bone
metastases were not confirmed during a mean clinical-imaging
follow-up over more than 47 months (range 12–120). Six (4%) of
these 136 non-relapsed patients with equivocal BS were selected
to undergo CT because of concomitant constant elevation or
progressive increase on tumour marker panel.
Relapsed patients
Table 2 shows the principal results of tests performed in the 47
relapsed patients. In these 47 relapsed patients the overall sensitiv-
ities for diagnosing bone metastases of baseline skeletal X-ray, BS
and tumour marker panel were 25%, 98% and 91.5% respectively.
In 14 (29.7%) equivocal (seven) or pathological (seven) BS was
the first sign of the relapse. Twenty-seven patients (57%) were
suspected for relapse because they showed constant elevation or
progressive increase in one or more tumour markers in the panel,
which was not explained by concomitant chronic or transient
benign pathology. In 15 of these 27 patients, BS was pathological,
and in the other 12 patients it showed a picture of equivocal inter-
pretation. In the other two (4.2%) of the 47 relapsed patients, base-
line skeletal X-ray was the first sign of the relapse. In one of these
two patients BS was pathological and in the other it was falsely
negative. Bone symptomatology occurred as a first sign of relapse
in the remaining four (8.5%) patients and lead-time to definite
radiological diagnosis was 5.5 ± 7 months. In three of these four
patients BS showed a picture of equivocal interpretation and in the
last it was pathological. In 23 relapsed patients bone symptoms
appeared either after patients were suspected due to tumour marker
increase (14 subjects) or when bone metastases were ascertained
by radiological means (nine patients). In the remaining 20 relapsed
patients bone symptoms occurred after bone metastases had been
radiologically ascertained. Therefore, at the time of relapse in 24
(51%) of the 47 patients with metastases the BS was pathological.
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Table 1 False positive results in diagnosing bone metastases in 250
nonrelapsed breast cancer patients
Test type Tn Result Probably Test specificity (%)
positive tests (n)
Tumour marker panel 3792 94+ 2 99
Bone scintigraphy 895 136e 136 46
Skeletal X-ray 250 7e 7 97
Tn = total number of tests; Result = number of patients with (e) equivocal
initial imaging result or (+) significantly elevated tumour marker panel
Table 2 False negative results in 47 breast cancer patients with bone metastases
Test type Tn Result Probably Test sensitivity (%)
negative tests (n)
Tumour marker panel 578 20 – 4 91.5
Bone scintigraphy 104 22 e 98
1 negative 1
Skeletal X-ray* 47 15 negative 15 25
Tn = total number of tests; Result = number of patients with (e) equivocal initial imaging result or (–) normal or not significantly
elevated tumour marker panel; *basal skeletal X-ray was evaluated in 20 patients with bone metastases in the first year after
mastectomyIn 22 (46.8%) it showed a picture of equivocal interpretation and
in one patient it was falsely negative. In this last patient (aged 53
years) with pT2N1M0 classification, BS maintained the same
picture until 33 months after the first falsely negative result. This
patient had an osteolytic lesion in the occipital bone which was
suspected to be a relapse because of the tumour marker panel and
was submitted to CT of the skull because of constant headache.
Twenty two (47%) (group b) of the 47 relapsed patients
showed a BS with an equivocal picture (Table 2). In this group b,
aged 32–77 years (53.5 ± 12; mean ± SD), premenopausal and
N+ patients were 41% and 59% respectively, and bone metastases
were confirmed by an average clinical-imaging follow-up over
more than 28 months (range 5–65). Eighteen (82%) of these 22
relapsed patients with equivocal BS showed constant elevation or
progressive increase on the tumour marker panel (Table 3) and
were selected to undergo CT (14) or rib X-ray (four).
The role of tumour markers in confirming or excluding
bone metastases in the patients with equivocal BS
Table 3 clearly shows that tumour markers were elevated among
relapsed patients in a significantly greater proportion than in
non-relapsed patients. Tumour markers remained normal or not
significantly elevated in patients without bone metastases much
more frequently than in those who relapsed (P = 0.02, Fisher’s
exact test).
DISCUSSION
The physician who cares for breast cancer patients after mastec-
tomy very often faces the clinical problem of how to distinguish
between benign and metastatic bone lesions without using
invasive procedures. He should therefore be well aware of the
accuracy of the available techniques.
This study shows that the sensitivity of baseline skeletal X-ray
for the ‘early’ detection of bone metastases is only 25%. BS is a
useful sensitive tool for the early diagnosis of bone metastases but
is not specific enough. Furthermore, in this study, it provided a
picture of equivocal interpretation in 53% of all patients (54% of
non-relapsed patients and 47% of patients with bone metastases).
Therefore, skeletal X-ray is not useful for the ‘early’ detection
of bone metastases due to low sensitivity (Galasko et al, 1972;
Komaki et al, 1979) and BS requires complementary tools, to
select patients to undergo radiological examinations directed to
those hot spots with equivocal interpretation. NMR and CT are
among the more recently developed techniques. NMR has been
reported to be very helpful for the ‘early’ detection of bone marrow
microdissemination from breast cancer. It allows for a better
staging; however, the diagnostic information provided is limited to
the regions of haemopoietic bone marrow (Sanal et al, 1994;
Moulopulos et al, 1995). In contrast, hot spots on whole body BS
commonly occur in compact portions of the bony skeleton. CT has
proved highly accurate in the diagnosis of bone lesions (Held et al,
1994). However CT and NMR may not be suitable for routine use
in the postoperative follow-up of breast cancer patients because
they are too expensive and time-consuming; furthermore, the
lesions examined are often benign. The sensitivity of the CEA-
TPA-CA15.3 panel to signal a relapse is very high (about 90%).
This high sensitivity for detecting distant metastases confirms our
previous data (Nicolini et al, 1991) and it is greater than that
reported by other authors for individual markers (50%, 67%, 77%
for CEA, CA15.3, TPA respectively) and for the combination of
CEA-CA15.3 (71%) (Luthgens et al, 1981; Fateh-Moghadam et al,
1993; ASCO tumour marker expert panel, 1996). The reason for
this greater sensitivity is probably because three markers are moni-
tored simultaneously (CEA, TPA and CA15.3): Moreover, we have
defined specific criteria to seek out false positive results on the
tumour marker panel (Nicolini et al, 1989, 1992).
In this study, we evaluated the utility of the CEA-TPA-CA15.3
tumour marker panel to select patients with equivocal BS at high
risk of bone metastases. In selecting patients with equivocal BS to
undergo radiological examinations, the CEA-TPA-CA15.3 tumour
marker panel showed 94% accuracy. In fact, among the 158
patients with equivocal BS (groups a + b) only four falsely nega-
tive and six falsely positive results of the tumour marker panel
were observed (Table 3).
These data indicate that in the postoperative follow-up of breast
cancer patients the CEA-TPA-CA15.3 tumour marker panel is a
suitable tool to select patients to undergo further radiological
examinations directed at the sites of equivocal BS findings and
that it allows a decrease of 70–80% in the number of bone scinti-
graphic studies and other radiological examinations (chest and
skeletal X-ray, liver echography, CT, NMR). Consequently, a
50–75% cost saving per patient is achieved for an intensive 
5-year follow-up with CEA-TPA-CA15.3 tumour marker panel,
compared with that conducted with traditional means. This cost
has been calculated as $10 000 per patient (Virgo, 1996) while in
our protocol it amounted to $2500.
As to the differential diagnosis between benign and malignant
skeletal lesions. CT showed high accuracy (70%) while skeletal
X-ray directed to equivocal hot spots shown at ribs by BS proved
unhelpful. Different examinations such as spiral CT and FDG PET
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Table 3 Tumour marker panel in patients with equivocal bone scintigraphy (BS)
Patients without bone metastases Patients with bone metastases
Equivocal BS (n) 136 22
Tumour marker panel + (n)6 1 8
Tumour marker panel – (n) 130 4
Tumour marker panel specificity 96% –
Tumour marker panel sensitivity – 82%
(+) significantly elevated; (–) normal or not significantly elevated tumour marker panel; P = 0.02, exact Fisher’s test(Shreve et al, 1996) should be evaluated for the differential diag-
nosis of equivocal BS areas in the ribs.
In conclusion, CEA-TPA-CA15.3 tumour marker panel can be
used as a preliminary screen to select those who need further
radiological investigation, thus confirming its important role in the
postoperative follow-up of breast cancer patients (Nicolini et al,
1997).
REFERENCES
ASCO Tumor Marker Expert Panel (1996) Clinical practice guidelines for the use of
tumor markers in breast and colorectal cancer. J Clin Oncol 14: 2843–2877
Bonadonna G and Valagussa P (1993) Neoplasie della mammella. In Manuale di
oncologia medica, Bonadonna G and Robustelli della Cuna G (eds), 
pp 529–563. Masson: Milano
Colman LK, Porter BA, Redmond J III, Olson DO, Stimac GK, Dunning DM and
Friedl KE (1988) Early diagnosis of spinal metastases by CT and MR studies. 
J Comput Assist Tomogr 12: 423–426
Cuschieri A (1973) Urinary hydroxyproline excretion in early and advanced breast
cancer – a sequential study. Brit J Surg 60: 800–803
Cuschieri A (1977) Urinary hydroxyproline in the management of breast cancer.
World J Surg 1: 299–302
Del Turco MR, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V (1994)
Intensive diagnostic follow-up after treatment of primary breast cancer. A
randomized trial. JAMA 271: 1593–1597
Fateh-Moghadam A and Stieber P (1993) Use of tumour markers in certain solid
tumours. In Sensible use of tumour markers, Fateh-Moghadam A, Stieber P
(eds), pp 56–57. J Hartmann, Verlag GMBH: Munich
Fogelman I (1991) Bone scanning. In Clinical Nuclear Medicine, 2nd edn, Maisey
MN, Britton KE and Gilday DL (eds), pp 131–157. Chapman and Hall
Medical: London
Galasko CSB and Doyle FH (1972) The detection of skeletal metastases from
mammary carcinoma. A regional comparison between radiology and
scintigraphy. Clin Radiol 23: 295–297
Gielen F, Dequeker J, Drochmans A, Wildiers J and Merlevede M (1976) Relevance
of hydroxyproline excretion to bone metastasis in breast cancer. Br J Cancer
34: 279–285
Guzzo CE, Pachas WN, Pinals RS and Krant MJ (1969) Urinary hydroxyproline
excretion in patients with cancer. Cancer 24: 382–387
Held P and Breit A (1994) Comparison of CT and MRI methods in diagnosis of
tumours of the para- and retropharingeal space and temporal bone. Bildgebung
6: 263–271
Komaki R, Donegan W, Manoli R and Yeh EL (1979) Prognostic value of
pretreatment bone scans in breast carcinoma. AJR 132: 877–881
Luthgens M, Schelegel G, Eklund G and Bjorklund B (1981) Correlation between
activity in breast cancer and CEA, TPA and eighteen common laboratory
procedures and the improvement by the combined use of CEA and TPA.
Tumour Diagnostik 2: 6–11
Meissner W and Warren S (1971) Neoplasms. In Pathology, 6th edn. Mosby: St.
Louis
Moulopulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI
and Alexanian R (1995) Prognostic significance of magnetic resonance
imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 13:
251–256
Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW and Martin TJ
(1984) The hypercalcemia of cancer-clinical implications and pathogenic
mechanisms. N Engl J Med 310: 1718–1722
Nicolini A, Carpi A, Di Marco G, Giuliani L, Giordani R and Palla S (1989) 
A rational postoperative follow-up with carcinoembryonic antigen, tissue
polypeptide antigen and urinary hydroxyproline in breast cancer patients.
Cancer 63: 2037–2046
Nicolini A, Colombini C, Luciani L, Carpi A and Giuliani L (1991) Evaluation of
serum CA 15-3 determination with CEA and TPA in the post-operative follow-
up of breast cancer patients. Br J Cancer 64: 154–158
Nicolini A, Carpi A and Tibaldi C (1992) The patients postoperative management of
breast cancer patient: new concepts. In Progress in Clinical Oncology, Carpi A,
Sagripanti A and Mittermayer CH (eds), pp 187–203. Sympomed Medical:
Munchen
Nicolini A, Anselmi L, Michelassi C and Carpi A (1997) Prolonged survival by
“early” salvage treatment of breast cancer patients: a retrospective six year
study. Br J Cancer 76: 1106–1111
Robinson LA (1997) Radioisotope-guided surgical biopsy of suspected osseous
metastases. Cancer Control 4: 517–522
Sanal SM, Flickinger FW, Caudell MJ and Sherry RM (1994) Detection of bone
marrow involvement in breast cancer with magnetic resonance imaging. J Clin
Oncol 12: 1415–1421
Shreve PD, Grossman HB, Gross MD and Wahl RL (1996) Metastatic prostate
cancer: initial findings of PET with 2-deoxy-2-(F-18) fluoro-D-glucose.
Radiology 199: 751–756
Touitou Y, Proust J, Klinger E and Nakache JP (1985) Biological and pathological
factors affecting plasma gamma-glutamyl transpeptidase and alkaline
phosphatase activity in the elderly. Clin Chim Acta 146: 1–10
Virgo KS (1996) The costs of cancer patient follow-up post-treatment. In: ASCO
Educational Book, pp 328–329. the American Society of Clinical Oncology:
Place
White DR, Maloney JJ III, Muss HB, Vance RP, Barnes P, Howard V, Rhyne L and
Cowan RJ (1979) Serum alkaline phosphatase determination-value in the
staging of advanced breast cancer. JAMA 242: 1147–1149
Non-invasive diagnosis of skeletal metastases in breast cancer 1447
British Journal of Cancer (1999) 79(9/10), 1443–1447 © Cancer Research Campaign 1999